IRVINE, Calif., Sept. 4, 2012 /PRNewswire/ -- This morning, Allergan, Inc. (NYSE: AGN) will mark the opening of the company's first large facility in the state of New Jersey. Company leaders will be joined by federal, state and local government officials, community leaders, physicians and employees as they officially open Allergan's new Research and Development (R&D) Center in Bridgewater, New Jersey.
"For more than 60 years, Allergan has built a proud history based on two fundamental principles - scientific innovation and focus on doctors and their patients," said David E.I. Pyott, Allergan's Chairman of the Board, President and Chief Executive Officer. "We will continue to increase our investment in R&D to fuel innovation and expect to spend over $1 billion in 2013. Our New Jersey clinical development site will allow us to benefit from the expertise of the many talented R&D professionals that reside in this state and, most importantly, bring novel medical therapies to patients across the world."
Allergan is a multi-specialty health care company, with headquarters in California, a presence in more than 100 countries and approximately 10,500 employees worldwide. The company originally opened a small office in Bedminster, NJ, in 2008. The new R&D Center, which will be specifically focused on clinical development, is a significant expansion of the company's footprint in New Jersey and is expected to eventually house several hundred employees.
"Our aggressive efforts to promote economic growth and foster job creation and investment in our state are delivering results for New Jerseyans. Allergan is a world-class, innovative company that is committing to our state and people with several hundred high quality, research and development new jobs," said Lt. Governor Kim Guadagno, who has led the Christie Administration's successful efforts to attract life science companies to New Jersey. "Creating good paying, private sector jobs that are sustainable over the long term is the number one priority of the Christie Administration.""I'm proud to join in celebrating this step forward for New Jersey's thriving biotech and health care community with the expansion of Allergan's operations to this new R&D facility, and especially proud to celebrate the hundreds of new, high-skill jobs it's bringing to New Jersey," said U.S. Senator Robert Menendez (D-NJ), a long-time supporter of expanding research and development efforts in biotechnology. "This new facility is an investment in America's future, an investment in New Jersey's economy and an investment in our nation's intellectual infrastructure." "We are delighted that Allergan, a multi-specialty health care company committed to uncovering the best of science, is expanding its R&D operation here in the heart of New Jersey. With our robust pool of highly skilled workers in the pharma and biotech sector, New Jersey offers the talent and the location to help advance medical research," said Congressman Leonard Lance (NJ-07). "Improving our economy is our number one priority, and Allergan's move - and the jobs it brings with it - make this a win-win for the company and our state's residents." About the R&D Center In line with Allergan's commitment to the environment and efforts regarding sustainability issues, the 93,000-square-foot facility features high-performance, energy-efficient and environmentally responsible energy systems that produce low emissions and optimal indoor air quality. The facility was awarded the U.S. Environmental Protection Agency's prestigious Energy Star recognition, the national symbol for superior energy efficiency and environmental protection, and is registered with Leadership in Energy and Environmental Design (LEED), which is the path to seeking LEED Existing Building – Operating & Maintenance certification. Forward-Looking Statements This press release contains "forward-looking statements", including but not limited to the statements by Mr. Pyott, Lt. Governor Guadagno, Senator Menendez and Congressman Lance. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and pharmaceutical market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new pharmaceutical and medical device products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2011 Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. About Allergan, Inc. Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 10,500 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: www.allergan.com. Allergan Contacts: Bonnie Jacobs (856) 912-9965 (media) Cathy Taylor (949) 293-4453 (media) Jim Hindman (714) 246-4636 (investors) Joann Bradley (714) 246-4766 (investors) David Nakasone (714) 246-6376 (investors) © 2012 Allergan, Inc. Irvine, CA 92612. ® marks owned by Allergan, Inc. All rights reserved.